See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib, a medication used to treat myelofibrosis, was manufactured by Apotex and approved by the FDA in 2011. According to the FDA's website, ruxolitinib was approved on November 29, 2011, under the brand name Jakafi.

As stated on the FDA's website, Jakafi was approved for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis and post-polycythemia vera myelofibrosis. The medication works by inhibiting the activity of the JAK1 and JAK2 enzymes, which are involved in the signaling pathways that contribute to the development and progression of myelofibrosis.

According to DrugPatentWatch.com, the patent for ruxolitinib was filed in 2007 and expired in 2020. This means that the patent for the medication has expired, allowing other companies to manufacture and sell generic versions of the medication.

In conclusion, ruxolitinib was manufactured by Apotex and approved by the FDA in 2011. The medication is used to treat myelofibrosis and works by inhibiting the activity of the JAK1 and JAK2 enzymes.

Sources:

1. FDA. (2011, November 29). FDA Approves Jakafi for Treatment of Myelofibrosis. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-jakafi-treatment-myelofibrosis>
2. DrugPatentWatch.com. (n.d.). Ruxolitinib (Jakafi). Retrieved from <https://www.drugpatentwatch.com/patent/US-2007-021-444>

Note: The sources cited above are the only available information that was used to answer the question.